EA201690863A1 - Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6) - Google Patents

Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6)

Info

Publication number
EA201690863A1
EA201690863A1 EA201690863A EA201690863A EA201690863A1 EA 201690863 A1 EA201690863 A1 EA 201690863A1 EA 201690863 A EA201690863 A EA 201690863A EA 201690863 A EA201690863 A EA 201690863A EA 201690863 A1 EA201690863 A1 EA 201690863A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
gas6
modulator
nuclein
methods
Prior art date
Application number
EA201690863A
Other languages
English (en)
Inventor
Кристофер Рускони
Джулиана Лейзер
Сэнджой К. Маханти
Кристофер Л. Десиантис
Кейти Редик
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Publication of EA201690863A1 publication Critical patent/EA201690863A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Abstract

Настоящее изобретение, в общем, относится к фармакологической системе для модулирования биологии тромбоцитов на основе нуклеиново-кислотных лигандов, которые могут взаимодействовать с и модулировать активность специфического белка гена блокировки роста 6 (GAS6). Эти нуклеиново-кислотные лиганды активно обратимы при использовани модулятора, который ингибирует активность нуклеиново-кислотного лиганда и нейтрализует его фармакологический эффект, тем самым восстанавливая функцию GAS6. Также предлагаются композиции, содержащие нуклеиново-кислотный лиганд, лиганд и модулятор, способы получения нуклеиново-кислотного лиганда и его модулятора, способы определения характеристик нуклеиново-кислотного лиганда, а также способы применения этих агентов и композиций в медицинских терапевтических и диагностических процедурах.
EA201690863A 2012-10-24 2013-10-17 Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6) EA201690863A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717949P 2012-10-24 2012-10-24
PCT/US2013/065521 WO2014066142A1 (en) 2012-10-24 2013-10-17 Nucleic acid regulation of growth arrest-specific protein 6 (gas6)

Publications (1)

Publication Number Publication Date
EA201690863A1 true EA201690863A1 (ru) 2016-09-30

Family

ID=50545127

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690863A EA201690863A1 (ru) 2012-10-24 2013-10-17 Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6)

Country Status (2)

Country Link
EA (1) EA201690863A1 (ru)
WO (1) WO2014066142A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208110A1 (en) 2018-11-30 2020-07-02 Cellphire, Inc. PLATELETS LOADED WITH mRNA
EP3886879A4 (en) 2018-11-30 2022-12-07 Cellphire Inc. PLATES AS DELIVERY AGENTS
WO2020227149A1 (en) 2019-05-03 2020-11-12 Cellphire, Inc. Materials and methods for producing blood products
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
CA3170201A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144237A1 (en) * 2000-04-13 2003-07-31 Peter Carmeliet Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
AU2002312059B2 (en) * 2001-05-25 2009-01-15 Duke University Modulators of pharmacological agents
AU2009273878A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand
PT2525824T (pt) * 2010-01-22 2017-07-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica antimetastática

Also Published As

Publication number Publication date
WO2014066142A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
PH12015501370A1 (en) Compounds and methods for kinase modulation, and indications therefor
EA201690863A1 (ru) Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6)
MY181106A (en) Anti-lag3 antibodies and uses thereof
EA201791007A2 (ru) Соединения и их применения для модуляции гемоглобина
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2018005332A (es) Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
MX358128B (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos.
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
IN2015KN00350A (ru)
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
NZ707831A (en) Agents for treatment of claudin expressing cancer diseases
WO2014039714A3 (en) Compounds and methods for kinase modulation, and indications therefor
EA201790134A3 (ru) Соединения имидазопирролидинонов
EA201690567A1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
EA202092627A1 (ru) Соединения и их применения для модуляции гемоглобина
WO2015132675A3 (en) Methods and compositions for modifying the immune response
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба